A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial
Salaminios G., Duffy L., Ades A., Araya R., Button KS., Churchill R., Croudace T., Derrick C., Dixon P., Dowrick C., Gilbody S., Hollingworth W., Jones V., Kendrick T., Kessler D., Kounali D., Lanham P., Malpass A., Peters TJ., Riozzie D., Robinson J., Sharp D., Thomas L., Welton NJ., Wiles N., Lewis G.
BACKGROUND: Depressive symptoms are usually managed within primary care and antidepressant medication constitutes the first-line treatment. It remains unclear at present which people are more likely to benefit from antidepressant medication. This paper describes the protocol for a randomised controlled trial (PANDA) to investigate the severity and duration of depressive symptoms that are associated with a clinically significant response to sertraline compared to placebo, in people presenting to primary care with depression.